an increased risk for DGF. In this regard, several predictive models for DGF have been developed within the last few years. [5, [7] [8] [9] [10] [11] These models contribute to the prediction and evaluation of kidney function in China DCD, however, not entirely suitable for China DCD. Therefore, it is of great significance to identify DGF by simple and easily accessible pretransplant variables.
In this study, the aim was to develop a simple donor risk score model that could be readily applied by physicians to evaluate the quality of DCD kidneys and identifies kidneys at the highest risk of DGF before DCD.
Methods

Ethical approval
The local institutional review board of the First Affiliated Hospital of Xi'an Jiaotong University approved the study protocol, which was in compliance with the provisions of the current Declaration of Helsinki principles and good clinical practice guidelines. All patients provided written informed consent for participation in the study and to have their medical data used for research purposes.
Study populations
We retrospectively reviewed the effects of all consecutive patients aged between 16 and 70 years who underwent primary DCD kidney transplantation at the First Affiliated Hospital of Xi'an Jiaotong University between December 1, 2011, and October 31, 2016. Recipients were excluded from the study if: (1) they had undergone re-transplantation, received an organ other than a kidney, or developed graft failure within 48 h of the transplant operation; (2) had a positive cross match or positive panel-reactive antibody (over 30%); (3) had an active infection, hepatitis, or abnormal hepatic function; or (4) had leukopenia (leukocytes <3000/mm 3 ), thrombocytopenia (platelets <100,000/mm 3 ), or severe anemia (hemoglobin <60 g/L). DCD donor inclusion criteria are the following: (1) identity, (2) negative HIV antigen test, (3) 16≤ age ≤65 years, and (4) negative diagnosis for the malignant tumor, drug abuse, or renal diseases.
Clinical data collection
Qualified patients from the entire database were randomized in a 2:1 manner to create development and validation cohorts, respectively. Patient and donor data were collected in electronic clinical patient charts. Based on previous studies [8, 10, 12] and our experience, the following risk factors were collected: donor characteristics (age, sex, cause of death [COD] , history of hypertension of diabetes, before donation estimated glomerular filtration rate [eGFR], hypotension process, vasopressor used, and cardiopulmonary resuscitation [CPR] event), cold and warm ischemia time, and recipient characteristics at the time of transplantation (age, sex, number of previous kidney transplantations, preexisting kidney disease, and number of human lymphocytic antigen mismatches). Graft outcome data were also recorded. DGF was defined as the need for dialysis within the 1 st week after transplantation. Graft failure was defined as return to hemodialysis, transplant nephrectomy, or recipient death with a functioning graft.
Immunosuppressant protocol
A triple immunosuppressive regimen was used in all patients of mycophenolic acid, calcineurin inhibitor, and prednisone. All patients received either basiliximab or rabbit antithymocyte globulin (ATG) as an induction therapy.
Basiliximab was given at a dose of 20 mg on postoperative days 0 and 4. ATG was given at 1.25 mg·kg −1 ·d −1 starting during the operation and for 3-5 days postoperatively.
Statistical analysis
Qualitative variables were presented as frequencies and percentages, and quantitative variables were presented as the means ± standard deviation (SD) or median. The donor risk score development cohort was initially used for identifying univariate associations between donor variables and DGF. Multivariate logistic regression analysis was then performed to identify independent predictors of DGF and to estimate odds ratios (ORs). The estimated ORs from the logistic model were used, giving an integer of 1 to each 0.5 value of OR. Donor variables that were significant in the univariate analysis were available for selection in the final model; a total of 1000 bootstrap samples were selected from the development cohort for the best subset of risk factors to avoid overfitting the data. For each sample, a stepwise selection procedure was used to choose independent predictors of DGF. Variables that were selected in ≥90% of the bootstrap models were included in the final multivariate models, the scoring method similar to that of Sullivan et al. [13] The predictive accuracy of the risk score was assessed by both discrimination measured by receiver operating characteristics curves and compared their C-statistics (area under the curve) and calibration evaluated by Hosmer-Lemeshow Chi-squared statistic. [14] The results were considered statistically significant for P < 0.05. All calculations were performed using SPSS 19.0 software (SPSS Inc., Chicago, IL, USA).
results
Demographic and clinical characteristics of donors and recipients
During the study period, 543 recipients of kidney transplant from DCD were recorded. Qualitative and quantitative variables were described according to the development (n = 362) and validation (n = 181) cohorts as summarized in Table 1 . As the allocation was random, the two groups were similar. The most common COD about donors in both groups was craniocerebral trauma (62.3% vs. 61.9%, respectively, P = 0.932), and the eGFR in donors immediately before organ procurement was slightly lower in development cohort versus validation cohort (92.8 ± 60.1 vs. 96.5 ± 65.9 ml·min −1 ·1.73 m − ², respectively, P = 0.537). There were no significant differences about demographic and clinical characteristics between these two groups with respect to donors and recipients [ Table 1 ]. The immunosuppressive regimen and induction program in two groups had no significant difference.
Uni-and multi-variate analyses of donor variables associated with delayed graft function in development cohort
Since this study focused on the donor risk factors before kidney donation, some of the receptors and postdonation risk factors are not included in the analysis. Based on previous studies, we selected 12 commonly used donor risk factors for DGF to analysis [ Table 2 ]. Eight donor variables (COD, history of hypertension, terminal eGFR, age, history of diabetes, hypotension process, vasopressor used, and CPR event) were found by univariate analysis to be significantly associated with DGF [ Table 3 ]. The history of diabetes approached significance in the multivariate analysis (P = 0.058).
Construction of the delayed graft function predictive score model
The methods of Sullivan et al. [13] were used to convert the model in Table 4 to a simple point system. The risk score was derived from a competing risk model with DGF in Table 3 . To calculate the risk score, points for all factors are summed. According to the results of uni-and multi-variate logistic regression analyses, the age (referent <50 years), history of hypertension (referent no.), hypotension process (referent ≤80 mmHg), COD (referent craniocerebral trauma), terminal eGFR (referent >60 ml·min ), vasopressor used (Referent No), and CPR event (Referent No) were identified as independent predictors of DGF, and those variables were selected for the final scoring model. The ORs and confidence intervals (CIs) were reported for each variable as summarized in Table 3 . The Hosmer-Lemeshow statistic was Chi-square = 9.05 (P = 0.422) for the donor risk score model, indicating that a logistic model was appropriate in the analyses. Risk scores based on the donor risk model for all predictors are shown in Table 4 . The resulting donor risk score [ Table 4 ] ranged between a minimum of 0 to a maximum of 28 points. Figure 1 depicts the frequency of DGF in both the development and validation cohorts. There was a clear increase in the incidence of DGF, moving from the low-to-very high-risk score group. Based on the obtained frequencies of DGF in relation to different risk scores, we formed four risk categories of increasing severity (low risk 0-4, moderate risk 5-9, high risk 10-14, and very high risk 15-28) to increase the number of patients in each risk category and to enhance the clinical utility of the score. The frequency of DGF across the four categories of severity in the development cohort set ranged between 4.5 and 64.5% [ Figure 2 ]. The observed overall frequency of DGF after kidney transplantation in the development cohort was 15.2% (n = 55).
Validation of the predictive capacity of the scoring model
The observed overall rate of DGF after kidney transplantation in the validation cohort was 16.0% (n = 29). The rates of DGF in the validation cohort were close to those in the development cohort inside each of the four risk categories [ Figure 2 ]. We did C-statistic analysis of the two datasets, to test and compare the diagnostic accuracy of the donor risk scoring model. The C-statistic for the donor risk score in the validation cohort was 0.783 (95% CI: 0.680-0.886), whereas it was 0.790 (95% CI: 0.683-0.897) in the development cohort; the C-statistics were not significantly different [ Figure 3 ], indicating that the donor risk score model demonstrated good discriminative power of DGF before kidney transplantation.
dIscussIon Donor organ quality has been recognized as one of the most crucial factors affecting graft function and survival in kidney transplantation. [4, 15, 16] How to evaluate the quality of DCD kidneys has become a critical problem on kidney transplantation field. Reduction of this complication might not only have important clinical significance, but also might bring huge economic benefits. Therefore, the pretransplant prediction model of DGF is a goal of global transplant scholars.
Kidney biopsy and histologic scores [17, 18] remain to be a gold standard for evaluating the quality of kidneys before transplantation. However, kidney biopsy is a time-consuming and invasive process that requires experienced pathologists to assess kidney quality. Hence, several studies evaluating potential donor risk factors for allograft dysfunction and loss in kidney transplantation have highlighted the importance of the organ characteristics independent of the transplant recipient in determining allograft function and survival. [5, [7] [8] [9] [10] 15] In this study, all the listed donor risk factors [ Table 2 ], with the exception of donor gender, BMI, ICU stay time before transplantation, and right or left kidney, were demonstrated to be predictive factors for DGF in univariate analysis. It has been reported that BMI and ICU stay time before transplantation were risk factors for DGF. [4, 6, 19] These discrepancies may be due in part to our exclusion of smaller body weight (weight <30 kg) and short ICU stay time before transplantation of the donor in this study. Donor's hypotension process and CPR event were found to be significantly correlated with DGF. These findings provide novel valuable information regarding the functional relationship of these emerging risk factors. As we know, The frequencies of delayed graft function in relation to different donor risk scores in development and validation cohorts. All donation after cardiac death kidney scores were no more than 18 points in both the groups. It is clear that, with the increase in donor risk score, the incidence of delayed graft function gradually increased.
assured. However, at high-risk categories, we recommend being cautious in the application of the DCD kidneys. Unfortunately, in very high-risk categories, we propose to abandon the application of DCD kidneys but should be based on the specific clinical situation. hypotension process [20] and CPR event [21] can cause acute kidney injury, while acute renal injury is an independent risk factor for DGF and renal function recovery. [22] [23] [24] The data support this connection. In the development cohort, donor variables such as age, history of hypertension, hypotension process, COD, terminal eGFR, vasopressor used, and CPR event were significantly associated with DGF multivariate analysis (history of diabetes in the borderline). Accordingly, we have established a donor risk scoring model to identify DGF at high as well as low_risk levels before transplantation [ Table 4 ]. Furthermore, we validated the donor risk score model, which was similar to that from the development cohort (0.783 vs. 0.790, respectively), suggesting high stability of the donor risk score model.
The present study derived and validated a potential clinical prediction tool rather than a decision rule. It is to aid the attending physician who will make the clinical decision. For instance, at low-and moderate-risk categories, we recommend that the DCD kidneys can be used rest The donor risk score categories. There was a clear increase in the incidence of delayed graft function moving from the low-to-very high-risk score group. The donor risk score derived from the development cohort predicted delayed graft function in the validation cohort, as well. In conclusion, we identified a pretransplantation predictive model for DGF, based on easily available donor variables. The donor risk score model might be a good noninvasive tool for evaluating the quality of DCD kidneys and potentially useful for physicians to make optimal decisions about donor organ offers. 
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